What do systematic reviews say?

Summary of findings: pioglitazone monotherapy vs no intervention

The review found no eligible studies for this question.

• Pioglitazone for prevention or delay of type 2 diabetes mellitus and its associated complications in people at risk… 2020 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Summary of findings table ‐ Rifampin/rifampicin vs placebo

The review found no eligible studies for this question.

• Pharmacological interventions for pruritus in adult palliative care patients 2024 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Summary of findings table ‐ Off‐midline closure vs tension‐free midline closure

The review found no eligible studies for this question.

• Midline and off‐midline wound closure methods after surgical treatment for pilonidal sinus 2024 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Summary of findings table ‐ Off‐midline closure vs conventional midline closure

The review found no eligible studies for this question.

• Midline and off‐midline wound closure methods after surgical treatment for pilonidal sinus 2024 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Summary of findings table ‐ Convalescent plasma vs human immunoglobulin

The review found no eligible studies for this question.

• Convalescent plasma for people with COVID‐19: a living systematic review 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Summary of findings table ‐ Newly‐diagnosed EOC: PARPi with chemotherapy vs chemotherapy alone

• Poly(ADP‐ribose) polymerase (PARP) inhibitors for the treatment of ovarian cancer 2022 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 744 participants
  Moderate

Summary of findings table ‐ Platelet transfusion vs open control

The review found no eligible studies for this question.

• Haemostatic therapies for stroke due to acute, spontaneous intracerebral haemorrhage 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Rituximab vs intravenous methylprednisolone

• Rituximab for thyroid‐associated ophthalmopathy 2022 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 27 participants
  Very low

Summary of findings table ‐ Kappa‐opioid agonists vs placebo

The review found no eligible studies for this question.

• Pharmacological interventions for pruritus in adult palliative care patients 2024 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Dopamine agonist vs placebo

• Dopamine agonists for the treatment of restless legs syndrome 2011 · Cochrane Headline outcomes only
  no estimate extracted
  17 studies · 4312 participants
  Moderate

Summary of findings – strontium ranelate vs placebo

• Treatment for osteoporosis in people with beta‐thalassaemia 2023 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 24 participants
  Very low

Summary of findings table ‐ Cannabis vs placebo

• Cannabis and cannabinoids for symptomatic treatment for people with multiple sclerosis 2022 · Cochrane Headline outcomes only
  no estimate extracted
  8 studies · 1942 participants
  Low

Summary of findings table ‐ Platinum‐sensitive recurrent EOC: PARPi monotherapy vs chemotherapy alone

• Poly(ADP‐ribose) polymerase (PARP) inhibitors for the treatment of ovarian cancer 2022 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 229 participants
  Low

Metformin vs megestrol

The review found no eligible studies for this question.

• Metformin for endometrial hyperplasia 2024 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Summary of findings 1. Amorphous hydrogel dressings vs other types of dressings

The review found no eligible studies for this question.

• Hydrogel dressings for donor sites of split‐thickness skin grafts 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Relaxation vs control

Summary of findings: relaxation showed no clear difference in quality of life Quality of Life Index ‐ dialysis version and Medical… compared with control (low certainty).

• Interventions for improving sleep quality in people with chronic kidney disease 2019 · Cochrane Headline outcomes only
  SMD 0.47
  2 studies · 138 participants
  Low

Anti‐VEGF vs control

Summary of findings: anti‐VEGF treatment probably leads to higher mean change in vision‐related quality of life compared with control (moderate certainty).

• Anti‐vascular endothelial growth factor for neovascular age‐related macular degeneration 2019 · Cochrane Headline outcomes only
  MD 6.69 [3.38, 9.99]
  2 studies · 1134 participants
  Moderate

Respiratory muscle training vs sham training or no training

• Respiratory muscle training for multiple sclerosis 2017 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 48 participants
  Low

Vitamin D vs placebo or usual care

The review found no eligible studies for this question.

• Vitamin D supplementation for the treatment of COVID‐19: a living systematic review 2021 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Hydroxyurea vs placebo

• Hydroxyurea (hydroxycarbamide) for sickle cell disease 2022 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 277 participants
  Low